LUNG vs. SKIN, NVRO, TCMD, GUTS, CERS, ANIK, TMCI, OSUR, TLSI, and SGHT
Should you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include Beauty Health (SKIN), Nevro (NVRO), Tactile Systems Technology (TCMD), Fractyl Health (GUTS), Cerus (CERS), Anika Therapeutics (ANIK), Treace Medical Concepts (TMCI), OraSure Technologies (OSUR), TriSalus Life Sciences (TLSI), and Sight Sciences (SGHT). These companies are all part of the "surgical & medical instruments" industry.
Pulmonx (NASDAQ:LUNG) and Beauty Health (NASDAQ:SKIN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Pulmonx presently has a consensus target price of $16.33, suggesting a potential upside of 81.48%. Beauty Health has a consensus target price of $6.29, suggesting a potential upside of 129.41%. Given Beauty Health's higher possible upside, analysts clearly believe Beauty Health is more favorable than Pulmonx.
In the previous week, Beauty Health had 23 more articles in the media than Pulmonx. MarketBeat recorded 24 mentions for Beauty Health and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.47 beat Beauty Health's score of 0.86 indicating that Pulmonx is being referred to more favorably in the media.
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 5.7% of Pulmonx shares are held by insiders. Comparatively, 41.7% of Beauty Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Beauty Health received 10 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 48.78% of users gave Beauty Health an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
Pulmonx has higher earnings, but lower revenue than Beauty Health. Pulmonx is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
Pulmonx has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Beauty Health has a net margin of -20.48% compared to Pulmonx's net margin of -80.46%. Beauty Health's return on equity of -0.02% beat Pulmonx's return on equity.
Summary
Beauty Health beats Pulmonx on 13 of the 18 factors compared between the two stocks.
Get Pulmonx News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
